Citations

Clear

2303 citation(s) found for "Yu, Edward".

Female Sex and Gender in Lung/Sleep Health and Disease: Increased Understanding of Basic Biological, Pathophysiological, and Behavioral Mechanisms Leading to Better Health for Female Patients with Lung Disease
Arteaga‐Solis, Emilio, Blenis, John , Bourjeily, Ghada , Clegg, Deborah J. , DeMeo, Dawn L. , Duffy, Jeanne F. , Gaston, B., Heller, Nicola , Jain, Raksha , Lahm, Tim , Lancaster, Lisa , Lee, Joyce , Legato, Marianne J. , McKee, Sherry A. , Mehra, Reena , Morris, Alison , Prakash, Y. S. , Gopal-Srivastava, Rashmi, Laposky, Aaron D., Punturieri, Antonello, Reineck, Lora A., Tigno, Xenia T., Gaston, Benjamin , Prakash, Y S , Han, MeiLan King , Hemnes, Anna R. , Henske, Elizabeth P. , Stämpfli, Martin R. , Clayton, Janine A. , Lee, Joyce S , Mehra, Reena

Mayo Clinic

American Journal of Respiratory and Critical Care Medicine | May 10, 2018 | Volume: 198 | Issue: 7 | Pages: 850-858

10.1164/rccm.201801-0168ws | PMID 29746147 Get It

Abstract Female sex/gender is an undercharacterized variable in studies related to lung development and disease. Notwithstanding, many aspects of lung and sleep biology and pathobiology are impacted by female sex and female reproductive transitions. These may manifest as differential gene expression or peculiar organ development. Some conditions are more prevalent in women, such as asthma and insomnia, or, in the case of lymphangioleiomyomatosis, are seen almost exclusively in women. In other diseases, presentation differs, such as the higher frequency of exacerbations experienced by women with chronic obstructive pulmonary disease or greater cardiac morbidity among women with sleep-disordered breathing. Recent advances in -omics and behavioral science provide an opportunity to specifically address sex-based differences and explore research needs and opportunities that will elucidate biochemical pathways, thus enabling more targeted/personalized therapies. To explore the status of and opportunities for research in this area, the NHLBI, in partnership with the NIH Office of Research on Women’s Health and the Office of Rare Diseases Research, convened a workshop of investigators in Bethesda, Maryland on September 18 and 19, 2017. At the workshop, the participants reviewed the current understanding of the biological, behavioral, and clinical implications of female sex and gender on lung and sleep health and disease, and formulated recommendations that address research gaps, with a view to achieving better health outcomes through more precise management of female patients with nonneoplastic lung disease. This report summarizes those discussions.
Endotracheal Tube Obstruction: Recognition and Management
Hosking, Michael P., Lennon, Robert L., Warner, Mark A. , Masley, Peter, DeLuca, Louis A., Didier, Edward P., Gray, John R.

Mayo Clinic

Military Medicine | May 8, 2018 | Volume: 154 | Issue: 10 | Pages: 489-491

10.1093/milmed/154.10.489 Get It

Novel Common Genetic Susceptibility Loci for Colorectal Cancer
Schmit, Stephanie L. , Edlund, Christopher K., Schumacher, Fredrick R. , Harrison, Tabitha A. , Huyghe, Jeroen R. , Qu, Chenxu, Melas, Marilena , Berg, David Van Den , Wang, Hansong, Tring, Stephanie, Plummer, Sarah J. , Alonso, M. Henar , Anton, Kristen , Aragaki, Aaron K. , Arndt, Volker , Barry, Elizabeth L. , Berndt, Sonja I. , Bloomer, Amanda M. , Boehm, Juergen , Brenner, Hermann , Brezina, Stefanie , Buchanan, Daniel D. , Butterbach, Katja, Caan, Bette J. , Carlson, Christopher S. , Castelao, Jose E. , Chang‐Claude, Jenny , Cheng, Ya‐Wen , Chin, Lee Soo, Church, Timothy R. , Correa, Marcia Cruz, Curtis, Keith R. , Duggan, David , Easton, Douglas F. , English, Dallas R. , Fischer, Rocky, Fritsche, Lars G. , Fuchs, Charles S. , Gago-Domínguez, Manuela , Gala, Manish , Gallinger, Steven , Gauderman, W. James, Giovannucci, Edward L. , Gogarten, Stephanie M. , González‐Villalpando, Clicerio, Gonzalez-Villalpando, Elena M., Greenson, Joel K. , Gsur, Andrea , Gunter, Marc J. , Haiman, Christopher A. , Hampe, Jochen , Harlid, Sophia , Harju, John F., Hayes, Richard B. , Hofer, Philipp , Hoffmeister, Michael , Huang, Shu-Chen, Huerta, José María , Hunter, David J., Idos, Gregory , Jackson, Rebecca D. , Jacobs, Eric J. , Jee, Sun Ha , Jenkins, Mark A. , Jia, Wei-Hua , Jiao, Shuo , Joshi, Amit D. , Kolonel, Laurence N. , Kono, Suminori , Krogh, Vittorio , Küehn, Tilman, Küry, Sébastien , LaCroix, Andrea Z. , Laurie, Cecelia , Lejbkowicz, Flavio, Lemire, Mathieu , Lenz, Heinz‐Josef , Levine, David , Li, Li , Lindor, Noralane M. , Liu, Yun-Ru, Lu, Yingchang , Luh, Frank , Ma, Jing , Mancao, Christoph , Manion, Frank J. , Markowitz, Sanford D. , Martín, Vicente , Matsuo, Keitaro , McDonnell, Kevin , McNeil, Caroline E, Murphy, Neil , Offit, Kenneth, Omichessan, Hanane , Cotoré, Jesús Paredes, Pérez‐Mayoral, Julyann, Rennert, Gad , Rennert, Hedy S., Riggs, Bridget M., Schafmayer, Clemens, Sellers, Thomas A. , Seminara, Daniela, Shibata, David , Siegel, Erin M. , Slattery, Martha L. , Stintzing, Sebastian , Taverna, Darin, Thibodeau, Stephen N. , Thomas, Duncan C. , Trichopoulou, Antonia , Duijnhoven, Fränzel J.B. van , Guelpan, Bethany van, Virtamo, Jarmo, Weinstein, Stephanie J. , Win, Aung Ko , Woods, Michael O. , Wu, Anna H. , Wu, Kana , Xiang, Yong-Bing , Zanke, Brent W., Zeng, Yi-Xin , Zhang, Ben , Zubair, Niha, Figueiredo, Jane C. , Lindblom, Annika , Moreno, Vı́ctor , Peters, Ulrike , Conti, David V. , Gruber, Stephen B. , Kühn, Tilman , Buchanan, Daniel D , Win, Aung K , Rennert, Gad , Hoffmeister, Michael , Arndt, Volker , English, Dallas R , Martín, Vicente , Moreno, Victor , Gunter, Marc J , Jenkins, Mark A , Van Den Berg, David J , Harrison, Tabitha A , Matsuo, Keitaro , Kury, Sebastien , Brenner, Hermann , Gago-Dominguez, Manuela , Hampe, Jochen , Murphy, Neil , Hayes, Richard B , Brezina, Stefanie , Conti, David V , Gong, Jian Feng , Albanes, Demetrius , Amos, Christopher I. , Bezieau, Stéphane , Bien, Stephanie A. , Boutron‐Ruault, Marie‐Christine , Campbell, Peter T. , Chan, Andrew T. , Chanock, Stephen Jacob , Cheng, Iona C. , Church, James M. , Coetzee, Gerhard A. , Cotterchio, Michelle , Feskens, Edith J. M. , FitzGerald, Liesel M. , Fortini, Barbara K. , Giles, Graham G. , Grady, William M. , Hopper, John L. , Hudson, Thomas J , Iwasaki, Motoki , Kooperberg, Charles , Li, Christopher I , Lieb, Wolfgang , Lin, Yi , Liu, Yun‐Ru , Loupakis, Fotios , Matsuda, Koichi , McNeil, Caroline E, Milne, Roger L. , Molina, Antonio José , Mukherjee, Bhramar , Newcomb, Polly A. , Palli, Domenico , Pharoah, Paul D.P. , Potter, John D. , Qu, Conghui , Raskin, Leon , Schoen, Robert E. , Severi, Gianluca , Shi, Wei , Shu, Xiao‐Ou , Southey, Melissa C. , Stadler, Zsofia , Stern, Mariana Carla , Tsugane, Shoichiro , Ulrich, Cornelia M. , Vijai, Joseph , White, Emily E. , Wolk, Alicja , Yen, Yun , Kweon, Sun-Seog , Zheng, Wei , Marchand, Loı̈c Le , Casey, Graham , Church, Timothy R , Caan, Bette J , Lindblom, Annika

Mayo Clinic

JNCI: Journal of the National Cancer Institute | April 30, 2018 | Volume: 111 | Issue: 2 | Pages: 146-157

10.1093/jnci/djy099 | PMID 29917119 Get It

Abstract Background Previous genome-wide association studies (GWAS) have identified 42 loci (P < 5 × 10−8) associated with risk of colorectal cancer (CRC). Expanded consortium efforts facilitating the discovery of additional susceptibility loci may capture unexplained familial risk. Methods We conducted a GWAS in European descent CRC cases and control subjects using a discovery–replication design, followed by examination of novel findings in a multiethnic sample (cumulative n = 163 315). In the discovery stage (36 948 case subjects/30 864 control subjects), we identified genetic variants with a minor allele frequency of 1% or greater associated with risk of CRC using logistic regression followed by a fixed-effects inverse variance weighted meta-analysis. All novel independent variants reaching genome-wide statistical significance (two-sided P < 5 × 10−8) were tested for replication in separate European ancestry samples (12 952 case subjects/48 383 control subjects). Next, we examined the generalizability of discovered variants in East Asians, African Americans, and Hispanics (12 085 case subjects/22 083 control subjects). Finally, we examined the contributions of novel risk variants to familial relative risk and examined the prediction capabilities of a polygenic risk score. All statistical tests were two-sided. Results The discovery GWAS identified 11 variants associated with CRC at P < 5 × 10−8, of which nine (at 4q22.2/5p15.33/5p13.1/6p21.31/6p12.1/10q11.23/12q24.21/16q24.1/20q13.13) independently replicated at a P value of less than .05. Multiethnic follow-up supported the generalizability of discovery findings. These results demonstrated a 14.7% increase in familial relative risk explained by common risk alleles from 10.3% (95% confidence interval [CI] = 7.9% to 13.7%; known variants) to 11.9% (95% CI = 9.2% to 15.5%; known and novel variants). A polygenic risk score identified 4.3% of the population at an odds ratio for developing CRC of at least 2.0. Conclusions This study provides insight into the architecture of common genetic variation contributing to CRC etiology and improves risk prediction for individualized screening.
Brentuximab vedotin plus bendamustine: a highly active first salvage regimen for relapsed or refractory Hodgkin lymphoma
LaCasce, Ann S. , Bociek, R. Gregory , Sawas, Ahmed , Caimi, Paolo, Agura, Edward, Matous, Jeffrey, Ansell, Stephen M. , Crosswell, Howland E. , Islas‐Ohlmayer, Miguel, Behler, Caroline, Cheung, Eric, Forero‐Torres, Andres , O’Connor, Owen A. , Josephson, Neil C. , Advani, Ranjana H. , Advani, Ranjana H , Vose, Julie M. , Wang, Yinghui

Mayo Clinic

Blood | April 27, 2018 | Volume: 132 | Issue: 1 | Pages: 40-48

10.1182/blood-2017-11-815183 | PMID 29703778 Get It

Key PointsThe outpatient BV and bendamustine regimen is highly active as first salvage therapy in relapsed/refractory HL, with manageable toxicity. The CR rate of 73.6% exceeded those reported for standard chemotherapy regimens, and post-ASCT outcomes generally appeared excellent.
WATER II (80–150 mL) procedural outcomes
Desai, Mihir , Bidair, Mo, Bhojani, Naeem , Trainer, Andrew, Arther, Andrew, Kramolowsky, Eugene V., Doumanian, Leo, Elterman, Dean , Kaufman, Ronald P., Lingeman, James E., Krambeck, Amy E. , Eure, Gregg , Badlani, Gopal , Plante, Mark , Uchio, Edward , Gin, Greg , Goldenberg, Larry , Paterson, Ryan F. , So, Alan , Humphreys, Mitch, Roehrborn, Claus, Kaplan, Steven A. , Motola, Jay , Zorn, Kevin C. , Bidair, Mohamed

Mayo Clinic

BJU International | April 25, 2018 | Volume: 123 | Issue: 1 | Pages: 106-112

10.1111/bju.14360 | PMID 29694702 Get It

Objectives To present early safety and feasibility data from a multicentre prospective study (WATER II) of aquablation in the treatment of symptomatic men with large‐volume benign prostatic hyperplasia ( BPH ). Methods Between September and December 2017, 101 men with moderate‐to‐severe BPH symptoms and prostate volume of 80–150 mL underwent aquablation in a prospective multicentre international clinical trial. Baseline demographics and standardized postoperative management variables were carefully recorded in a central independently monitored database. Surgeons answered analogue scale questionnaires on intra‐operative technical factors and postoperative management. Adverse events up to 1 month were adjudicated by an independent clinical events committee. Results The mean (range) prostate volume was 107 (80–150) mL. The mean (range) operating time was 37 (15–97) min and aquablation resection time was 8 (3–15) min. Adequate adenoma resection was achieved with a single pass in 34 patients and with additional passes in 67 patients (mean 1.8 treatment passes), all in a single operating session. Haemostasis was achieved using either a Foley balloon catheter placed in the bladder under traction ( n = 98, mean duration 18 h) or direct tamponade using a balloon inflated in the prostate fossa ( n = 3, mean duration 15 h). No patient required electrocautery for haemostasis at the time of the primary procedure. The mean length of stay after the procedure was 1.6 days (range same day to 6 days). The Clavien–Dindo grade ≥2 event rate observed at 1 month was 29.7%. Bleeding complications were recorded in 10 patients (9.9%) during the index procedure hospitalization prior to discharge, and included six (5.9%) peri‐operative transfusions. Conclusions Aquablation is feasible and safe in treating men with men with large prostates (80–150 mL). The 6‐month efficacy data are being accrued and will be presented in future publications (ClinicalTrials.gov number, NCT 03123250).
VP-16, Cyclophosphamide, Adriamycin and Cis-platinum (V:CAP-I) in Patients with Metastatic Adenocarcinoma of the Lung
Eagan, Robert T., Creagan, Edward T. , Rubin, Joseph, Frytak, Stephen, Kvols, Larry K., Fleming, Thomas R. , Ingle, James N.

Mayo Clinic

Tumori Journal | April 23, 2018 | Volume: 65 | Issue: 1 | Pages: 105-109

10.1177/030089167906500112 | PMID 442215 Get It

In an attempt to improve upon the 42% regression rate of the CAP-I regimen in patients with advanced adenocarcinoma of the lung, VP-16 was added to that regimen. VP-16, as a single agent, had a response rate of 12.5% (3/24) in a similar group of patients. The new regimen, V:CAP-I, had a tumor regression rate of 35% (7/20) and an estimated median survival of 171 days. Hence, we were unable to conclude that the addition of VP-16 to the CAP-I regimen statistically improved the regression rate of the CAP-I regimen.
Phase II Study of Everolimus in Metastatic Malignant Melanoma (NCCTG-N0377, Alliance)
Aguilera, Jesus Vera, Rao, Ravi D. , Allred, Jacob B., Windschitl, Harold E., Kaur, Judith S. , Maples, William J., Lowe, Val J. , Creagan, Edward T. , Vera Aguilera, Jesus, Suman, Vera J. , Erickson, Lori A. , Markovic, Svetomir N.

Mayo Clinic

The Oncologist | April 17, 2018 | Volume: 23 | Issue: 8 | Pages: 887-e94

10.1634/theoncologist.2018-0100 | PMID 29666297 Get It

Abstract Lessons Learned Everolimus does not have sufficient activity to justify its use as single agent in metastatic melanoma. Patients treated with 10 mg per day dose were most likely to require dose reductions. Everolimus appeared to reduce the numbers of regulatory T cells in approximately half of the treated patients; unfortunately, these effects were not correlated with clinical outcomes. Background Everolimus (RAD-001) is an orally active rapamycin analogue shown in preclinical data to produce cytostatic cell inhibition, which may be potentially beneficial in treating melanoma. We conducted a phase II study to evaluate the efficacy and safety of everolimus in patients with unresectable metastatic melanoma (MM). Methods This study included two cohorts; cohort 1 received 30 mg of everolimus by mouth (PO) weekly, and cohort 2 was dosed with 10 mg of everolimus PO daily. The endpoints of the study were safety, 16-week progression-free survival (PFS), overall survival (OS), and measures of immunomodulatory/antiangiogenic properties with therapy. Tumor samples before therapy and at week 8 of treatment were analyzed. Peripheral blood plasma or mononuclear cell isolates collected prior to therapy and at weeks 8 and 16 and at time of tumor progression were analyzed for vascular endothelial growth factor and regulatory T-cell (Treg) measurements. Results A total of 53 patients were enrolled in cohort 1 (n = 24) and cohort 2 (n = 29). Only 2 patients of the first 20 patients enrolled in cohort 2 had treatment responses (25%; 95% confidence interval, 8.6%–49.1%); this result did not allow full accrual to cohort 2, as the study was terminated for futility. Median OS was 12.2 months for cohort 1 versus 8.1 months in cohort 2; no PFS advantage was seen in either group (2.1 months vs. 1.8 months). Dose-limiting toxicities included grade 4 myocardial ischemia (3.4%); grade 3 fatigue, mucositis, and hyperglycemia (10.3%); and anorexia and anemia (6.9%). Everolimus significantly reduced the number of Tregs in approximately half of the treated patients; however, these effects were not correlated with clinical outcomes. Conclusion Everolimus does not have sufficient single-agent activity in MM; however, we have identified evidence of biological activity to provide a potential rationale for future combination studies.
Predictors of Durability of Radiological Response in Patients With Small Bowel Crohn’s Disease
Deepak, Parakkal , Fidler, Jeff L. , Barlow, John M. , Sheedy, Shannon P. , Kolbe, Amy B. , Harmsen, William S. , Therneau, Terry M. , Becker, Brenda D., Loftus, Edward V. , Bruining, David H. , Loftus, Edward V , Deepak, Parakkal , Fletcher, Joel G. , Fidler, Jeff L. , Hansel, Stephanie L.

Mayo Clinic

Inflammatory Bowel Diseases | April 13, 2018 | Volume: 24 | Issue: 8 | Pages: 1815-1825

10.1093/ibd/izy074 | PMID 29668921 Get It

Autologous transplantation versus allogeneic transplantation in patients with follicular lymphoma experiencing early treatment failure
Smith, Sonali M. , Godfrey, James , Ahn, Kwang Woo , Digilio, Alessandro, Ahmed, Sairah , Bachanová, Veronika , Bashey, Asad, Bolaños‐Meade, Javier , Cairo, Mitchell S. , Chen, Andy , Copelan, Edward A. , Aljurf, Mahmoud , Farooq, Umar , Ganguly, Siddhartha , Holmberg, Leona , Inwards, David J. , Kanate, Abraham S. , Karmali, Reem , Kenkre, Vaishalee P. , Kharfan‐Dabaja, Mohamed A. , Klein, Andreas K. , Mei, Matthew , Geethakumari, Praveen Ramakrishnan , Saad, Ayman , Schouten, Harry C. , Shah, Nirav N. , Urbano-Ispizúa, Álvaro , Vij, Ravi , Sureda, Anna , Holmberg, Leona , Bachanova, Veronika , Inwards, David, Mussetti, Alberto , Savani, Bipin N , Sureda, Anna , Hamadani, Mehdi , Chen, Andy I. , Saad, Ayman , Mei, Matthew , Farooq, Umar , Ahmed, Sairah , Karmali, Reem , Agrawal, Vaibhav , Bacher, Ulrike , Chhabra, Saurabh , Dahi, Parastoo B , Hertzberg, Mark , Lazarus, Hillard M. , Mussetti, Alberto , Nishihori, Taiga , Savani, Bipin N. , Vose, Julie M. , Hamadani, Mehdi

Mayo Clinic

Cancer | April 12, 2018 | Volume: 124 | Issue: 12 | Pages: 2541-2551

10.1002/cncr.31374 | PMID 29645093 Get It

BACKGROUNDEarly treatment failure (ETF) in follicular lymphoma (FL), defined as relapse or progression within 2 years of frontline chemoimmunotherapy, is a newly recognized marker of poor survival and identifies a high‐risk group of patients with an expected 5‐year overall survival (OS) rate of approximately 50%. Transplantation is an established option for relapsed FL, but its efficacy in this specific ETF FL population has not been previously evaluated.METHODSThis study compared autologous hematopoietic stem cell transplantation (auto‐HCT) with either matched sibling donor (MSD) or matched unrelated donor (MUD) allogeneic hematopoietic cell transplantation (allo‐HCT) as the first transplantation approach for patients with ETF FL (age ≥ 18 years) undergoing auto‐HCT or allo‐HCT between 2002 and 2014. The primary endpoint was OS. The secondary endpoints were progression‐free survival, relapse, and nonrelapse mortality (NRM).RESULTSFour hundred forty FL patients had ETF (auto‐HCT, 240; MSD hematopoietic stem cell transplantation [HCT], 105; and MUD HCT, 95). With a median follow‐up of 69 to 73 months, the adjusted probability of 5‐year OS was significantly higher after auto‐HCT (70%) or MSD HCT (73%) versus MUD HCT (49%; P = .0008). The 5‐year adjusted probability of NRM was significantly lower for auto‐HCT (5%) versus MSD (17%) or MUD HCT (33%; P < .0001). The 5‐year adjusted probability of disease relapse was lower with MSD (31%) or MUD HCT (23%) versus auto‐HCT (58%; P < .0001).CONCLUSIONSPatients with high‐risk FL, as defined by ETF, undergoing auto‐HCT for FL have low NRM and a promising 5‐year OS rate (70%). MSD HCT has lower relapse rates than auto‐HCT but similar OS. Cancer 2018;124:2541‐51. © 2018 American Cancer Society.